Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. QIAGEN N.V.
  6. News
  7. Summary
    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

QIAGEN N : supports White House COVID-19 vaccination, test mandate

09/10/2021 | 01:11pm EDT

Sept. 10 (Reuters) - German genetic testing specialist Qiagen said on Friday it supported Biden administration's new COVID-19 vaccination and testing mandate for workplaces.

"We strongly support all initiatives aiming to increase vaccination rates especially at the workplace," the company told Reuters in an email.

Qiagen said it had already updated its policies to make vaccination compulsory for certain employee groups at its U.S. locations.

U.S. President Joe Biden on Thursday announced policies requiring most federal employees to get COVID-19 vaccinations and pushing large and small private employers to have their workers inoculated or tested weekly.

The White House said it will spend nearly $2 billion on 280 million rapid COVID-19 tests to support the drive.

Abbott Laboratories, one of the largest U.S. manufacturers of rapid COVID-19 tests, said it was quickly working to scale up manufacturing of its two tests - BinaxNOW and ID NOW test kits - including hiring additional employees.

Increased capacity will ensure availability of tens of millions more tests in the coming weeks and months, the medical device maker said.

The new vaccination mandate could apply to as many as 100 million Americans - close to two-thirds of the country's workforce - and amount to Biden's strongest push yet for inoculation.

Southwest Airlines Co, which has more than 54,000 employees, said it was prepared to move toward compliance with the mandate.

"We continue to strongly encourage our Employees to seek and obtain vaccination, and to share their vaccination status with us," the company said. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)


© Reuters 2021
All news about QIAGEN N.V.
10/14QIAGEN N : Redburn Starts Qiagen NV at Buy
MT
10/12QIAGEN N.V. : Release of a capital market information
DJ
10/08QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German Securitie..
DJ
10/08QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German Securitie..
EQ
10/07QIAGEN NV : NorldLB sticks Neutral
MD
10/07QIAGEN NV : Receives a Buy rating from Deutsche Bank
MD
10/06PRESS RELEASE : BioRiver selects three innovative therapeutic and diagnostic approaches as..
DJ
10/05QIAGEN N.V. : Release of a capital market information
DJ
10/01QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German Securitie..
EQ
10/01QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German Securitie..
DJ
More news
Analyst Recommendations on QIAGEN N.V.
More recommendations
Financials (USD)
Sales 2021 2 155 M - -
Net income 2021 449 M - -
Net Debt 2021 907 M - -
P/E ratio 2021 26,3x
Yield 2021 -
Capitalization 11 717 M 11 717 M -
EV / Sales 2021 5,86x
EV / Sales 2022 6,01x
Nbr of Employees 5 900
Free-Float 98,3%
Chart QIAGEN N.V.
Duration : Period :
QIAGEN N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 51,64 $
Average target price 55,96 $
Spread / Average Target 8,36%
EPS Revisions
Managers and Directors
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Chief Financial Officer & Managing Director
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
QIAGEN N.V.-2.29%11 717
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414